These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35083525)

  • 1. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
    Avivi I; Perry C; Segman Y; Amit O; Bar-On Y; Katz OB; Gold R; Ribakovsky E; Avigdor A; Vainstein V; Goldschmidt N; Ringelstein-Harlev S; Horowitz NA; Gutwein O; Gurion R; Itchaki G; Abadi U; Nemets A; Sofer O; Vezker M; Tadmor T; Dally N; Filanovsky K; Leiba M; Sarid N; Benyamini N; Luttwak E; Herishanu Y; Ram R
    Ann Hematol; 2022 Apr; 101(4):755-762. PubMed ID: 35083525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
    Rattanathammethee T; Norasetthada L; Bunworasate U; Wudhikarn K; Julamanee J; Noiperm P; Lanamtieng T; Phiphitaporn P; Navinpipat M; Kanya P; Jit-Ueakul D; Wongkhantee S; Suwannathen T; Chaloemwong J; Wong P; Makruasi N; Khuhapinant A; Prayongratana K; Niparuck P; Kanitsap N; Suwanban T; Intragumtornchai T
    Ann Hematol; 2023 Jul; 102(7):1887-1895. PubMed ID: 37202499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
    Morita Y; Yagi Y; Kanemasa Y; Sasaki Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Ohashi K; Shimoyama T
    Rinsho Ketsueki; 2023; 64(7):586-595. PubMed ID: 37544717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
    Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ
    J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
    Vodicka P; Benesova K; Janikova A; Prochazka V; Belada D; Mocikova H; Steinerova K; Duras J; Karban J; Hanackova V; Sykorova A; Obr A; Trneny M
    Eur J Haematol; 2022 Aug; 109(2):162-165. PubMed ID: 35502609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
    Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
    Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
    Liebers N; Duell J; Fitzgerald D; Kerkhoff A; Noerenberg D; Kaebisch E; Acker F; Fuhrmann S; Leng C; Welslau M; Chemnitz J; Middeke JM; Weber T; Holtick U; Trappe R; Pfannes R; Liersch R; Spoer C; Fuxius S; Gebauer N; Caillé L; Geer T; Koenecke C; Keller U; Claus R; Mougiakakos D; Mayer S; Huettmann A; Pott C; Trummer A; Wulf G; Brunnberg U; Bullinger L; Hess G; Mueller-Tidow C; Glass B; Lenz G; Dreger P; Dietrich S
    Blood Adv; 2021 Jul; 5(13):2707-2716. PubMed ID: 34196677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
    Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H
    Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data.
    Sehn LH; Hertzberg M; Opat S; Herrera AF; Assouline S; Flowers CR; Kim TM; McMillan A; Ozcan M; Safar V; Salles G; Ku G; Hirata J; Chang YM; Musick L; Matasar MJ
    Blood Adv; 2022 Jan; 6(2):533-543. PubMed ID: 34749395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey.
    Dal MS; Ulu BU; Uzay A; Akay OM; Beşışık S; Yenerel MN; Çelik S; Kaynar L; Yücel OK; Deveci B; Sönmez M; Mehtap Ö; Beköz HS; Sunu C; Salim O; Ulaş T; Kartı S; Altuntaş F; Ferhanoğlu B; Tuğlular TF
    Ann Hematol; 2023 Jan; 102(1):133-140. PubMed ID: 36401621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cohort study of efficacy and safety of polatuzumab vedotin combined with immunochemotherapy in patients with relapse/refractory diffuse large B cell lymphoma].
    Wu JQ; Liu YY; Li F; Wu XZJ; Yao ZH; Kong FC; Zhou WL; Tang WY; Teng Y; Feng JF
    Zhonghua Yi Xue Za Zhi; 2021 Jul; 101(25):1985-1990. PubMed ID: 34225420
    [No Abstract]   [Full Text] [Related]  

  • 13. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
    Walji M; Assouline S
    Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
    Topp MS; Eradat H; Florschütz A; Hochhaus A; Wrobel T; Walewski J; Knopinska-Posluszny W; Kanate AS; Lech-Maranda E; Brunnberg U; Chitra S; Nielsen TG; Sellam G; Shivhare M; Lossos IS
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):811-817. PubMed ID: 35182224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
    Kim J; Cho J; Yoon SE; Kim WS; Kim SJ
    Cancer Res Treat; 2023 Jul; 55(3):1031-1047. PubMed ID: 36915243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models.
    Kawasaki N; Tomita M; Yamashita-Kashima Y; Yoshimura Y; Yoshiura S
    Leuk Lymphoma; 2023 Dec; 64(12):1938-1948. PubMed ID: 37548343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
    Segman Y; Ribakovsky E; Avigdor A; Goldhecht Y; Vainstein V; Goldschmidt N; Harlev S; Horwitz N; Gutwein O; Gurion R; Itchaki G; Abadi U; Nemets A; Sofer O; Zektser M; Tadmor T; Dally N; Filanovsky K; Leiba M; Sarid N; Benyamini N; Herishanu Y; Ram R; Perry C; Avivi I
    Leuk Lymphoma; 2021 Jan; 62(1):118-124. PubMed ID: 32981410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Lu T; Gibiansky L; Li X; Li C; Shi R; Agarwal P; Hirata J; Miles D; Chanu P; Girish S; Jin JY; Lu D
    Leuk Lymphoma; 2020 Dec; 61(12):2905-2914. PubMed ID: 32705923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
    Dimou M; Papageorgiou SG; Stavroyianni N; Katodritou E; Tsirogianni M; Kalpadakis C; Banti A; Arapaki M; Iliakis T; Bouzani M; Verrou E; Spanoudakis E; Giannouli S; Marinakis T; Mandala E; Mparmparousi D; Sachanas S; Dalekou-Tsolakou M; Hatzimichael E; Vadikolia C; Violaki V; Poziopoulos C; Tsirkinidis P; Chatzileontiadou S; Vervessou E; Ximeri M; Sioni A; Konstantinidou P; Kyrtsonis MC; Siakantaris MP; Angelopoulou MK; Pappa V; Konstantopoulos K; Panayiotidis P; Vassilakopoulos TP
    Hematol Oncol; 2021 Aug; 39(3):336-348. PubMed ID: 33583077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma].
    Lu Y; Liu H; Ye SG; Zhou LL; Luo X; Dang XY; Yuan XG; Qian WB; Liang AB; Li P
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):813-819. PubMed ID: 38049332
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.